GRFSGrifols, S.A.
Is the business good?
The checks split: nothing decisive, though earnings fully cash-backed (1.0×).
Operating profit is fully backed by cash.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
A balanced mix of margins, efficiency, and leverage. ROE 8% = margin × turnover × leverage.
Unless marked, from derived.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is GRFS?
Grifols, S.A. keeps 17% of every revenue dollar as operating profit, against 24% for the median Drug Manufacturers - General name.
Operating margin · Drug Manufacturers - General median 24% · fiscal year to FY2025
- Cash conversion
- 1.04×
Cash conversion · 0.96× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- +0.24%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 5.7%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 19% |
| FY2021 | 12% |
| FY2022 | 13% |
| FY2023 | 12% |
| FY2024 | 17% |
| FY2025 | 17% |
Details›
- Gross marginfiscal year to FY2025
- 38%
- Operating marginfiscal year to FY2025
- 17%
- Net marginfiscal year to FY2025
- 5.3%
- Free cash flow margin
- 10%
- R&D as % of revenue
- 5.7%
- Revenue, trailing twelve months
- $7.52B
- Free cash flow, trailing twelve months
- $782M
- Net income, trailing twelve months
- $402M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, General
Ranks #3 of 7 by RyuScore